New targeted pill may keep ALK lung cancer in check after standard treatment
NCT ID NCT07235306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the targeted drug ensartinib can help people with ALK-mutated stage III lung cancer that cannot be removed by surgery. After completing standard chemoradiotherapy, 45 participants will receive either ensartinib or a placebo to see if the drug delays cancer growth. The goal is to improve disease control without a cure, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.